Acer Therapeutics (NASDAQ:ACER) and NeuroVive Pharmaceutical (OTCMKTS:NEVPF) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.
Valuation and Earnings
This table compares Acer Therapeutics and NeuroVive Pharmaceutical’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Acer Therapeutics||N/A||N/A||-$21.28 million||($2.49)||-1.53|
|NeuroVive Pharmaceutical||N/A||N/A||-$7.87 million||($0.11)||-1.30|
Acer Therapeutics is trading at a lower price-to-earnings ratio than NeuroVive Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
This table compares Acer Therapeutics and NeuroVive Pharmaceutical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings and recommmendations for Acer Therapeutics and NeuroVive Pharmaceutical, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Acer Therapeutics currently has a consensus target price of $26.75, suggesting a potential upside of 603.95%. Given Acer Therapeutics’ higher possible upside, equities research analysts clearly believe Acer Therapeutics is more favorable than NeuroVive Pharmaceutical.
Institutional & Insider Ownership
25.9% of Acer Therapeutics shares are held by institutional investors. 20.1% of Acer Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Volatility & Risk
Acer Therapeutics has a beta of 1.61, suggesting that its stock price is 61% more volatile than the S&P 500. Comparatively, NeuroVive Pharmaceutical has a beta of 1.83, suggesting that its stock price is 83% more volatile than the S&P 500.
Acer Therapeutics Company Profile
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes three clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; and ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders, maple syrup urine disease, and osanetant for the treatment of various neuroendocrine disorders. The company was founded in 2013 and is headquartered in Newton, Massachusetts.
NeuroVive Pharmaceutical Company Profile
NeuroVive Pharmaceutical AB (publ) engages in the research and development of mitochondrial medicine in Sweden and internationally. Its product portfolio includes NeuroSTAT, a drug candidate that is in phase II clinical trial for the treatment of traumatic brain injuries; and KL1333 that is in phase I clinical trial for the treatment of genetic mitochondrial diseases. The company also develops NVP015/NV354 drug candidates for mitochondrial diseases; NVP025 drug candidate for mitochondrial myopathies; NV556 and NVP022 drug candidates for non-alcoholic steatohepatitis conditions; and NVP024, a hepatocellular carcinoma program. NeuroVive Pharmaceutical AB (publ) has collaboration agreements with Isomerase Therapeutics, Sihuan Pharmaceutical, and Sanofi Korea. The company also has a preclinical collaboration agreement with the Children’s Hospital of Philadelphia for research in genetic mitochondrial disorders. NeuroVive Pharmaceutical AB (publ) was founded in 2000 and is headquartered in Lund, Sweden.
Receive News & Ratings for Acer Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Acer Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.